Ernexa Therapeutics (ERNAW) Depreciation & Amortization (CF) (2010 - 2026)

Ernexa Therapeutics (ERNAW) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $8000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 55.56% year-over-year to $8000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55000.0 (down 53.39% YoY) and the FY2025 annual result came in at $65000.0, down 53.24% from the prior year.
• Depreciation & Amortization (CF) eased to $8000.0 in Q1 2026, from $13000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $68000.0 in Q2 2022 to a low of $8000.0 in Q1 2026.
• A 5-year average of $26882.4 and a median of $21000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 69.12% — and 2024, when it surged 109.52%.
• Tracing ERNAW's Depreciation & Amortization (CF) over 5 years: stood at $17000.0 in 2022, then grew by 29.41% to $22000.0 in 2023, then decreased by 13.64% to $19000.0 in 2024, then slumped by 31.58% to $13000.0 in 2025, then slumped by 38.46% to $8000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $13000.0 (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.